GSK plc (GSK.L) Stock Price

GSK plc Price

🇬🇧LSE·CLOSED
0.19GBP
Market closed
Today +/-
Today %

GSK plc (GSK.L) Stock | ISIN GB00BN7SWP63 | WKN 940561. The current GSK plc stock price is 0.19 GBP (2026). Revenue is 34.87 B GBP. Net income is 7.7 B GBP. The P/E ratio is 0.1. Market capitalization is 789.64 M GBP. GSK plc operates in the Health sector.

GSK plc stock price

Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of GSK plc over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how GSK plc stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing GSK plc's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

GSK plc Stock Price History
DateGSK plc Price
Access this data via the Eulerpool API
Get Free API Key

GSK plc Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2006
23.23 B GBP
7.62 B GBP
5.39 B GBP
Jan 1, 2007
22.72 B GBP
7.36 B GBP
5.21 B GBP
Jan 1, 2008
24.35 B GBP
8.04 B GBP
4.6 B GBP
Jan 1, 2009
28.37 B GBP
8.82 B GBP
5.53 B GBP
Jan 1, 2010
28.39 B GBP
4.96 B GBP
1.63 B GBP
Jan 1, 2011
27.39 B GBP
8.18 B GBP
5.26 B GBP
Jan 1, 2012
26.43 B GBP
7.88 B GBP
4.57 B GBP
Jan 1, 2013
26.51 B GBP
7.2 B GBP
5.44 B GBP
Jan 1, 2014
23.01 B GBP
5.48 B GBP
2.76 B GBP
Jan 1, 2015
23.92 B GBP
4.97 B GBP
8.42 B GBP
Jan 1, 2016
27.89 B GBP
7.04 B GBP
912 M GBP
Jan 1, 2017
30.19 B GBP
7.99 B GBP
1.53 B GBP
Jan 1, 2018
30.82 B GBP
8.36 B GBP
3.62 B GBP
Jan 1, 2019
33.75 B GBP
8.88 B GBP
4.65 B GBP
Jan 1, 2020
24.35 B GBP
5.99 B GBP
5.75 B GBP

GSK plc Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jun 10, 2026, 4:07 PM
 
REVENUE (M GBP)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M GBP)
NET INCOME (M GBP)
NET INCOME GROWTH (%)
DIV. (GBP)
DIV. GROWTH (%)
SHARES (M)
DOCUMENTS
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales GSK plc generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue GSK plc retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare GSK plc's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares GSK plc has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against GSK plc's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

GSK plc stock margins

The GSK plc margin analysis displays the gross margin, EBIT margin, as well as the profit margin of GSK plc. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for GSK plc.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2006
78.43 %
32.83 %
23.2 %
Jan 1, 2007
76.59 %
32.39 %
22.95 %
Jan 1, 2008
76.28 %
33.01 %
18.9 %
Jan 1, 2009
74.99 %
31.08 %
19.5 %
Jan 1, 2010
73.92 %
17.46 %
5.76 %
Jan 1, 2011
73.49 %
29.85 %
19.21 %
Jan 1, 2012
71.79 %
29.82 %
17.27 %
Jan 1, 2013
69.82 %
27.16 %
20.51 %
Jan 1, 2014
69.41 %
23.82 %
11.98 %
Jan 1, 2015
66.38 %
20.76 %
35.2 %
Jan 1, 2016
68.09 %
25.26 %
3.27 %
Jan 1, 2017
69.13 %
26.46 %
5.08 %
Jan 1, 2018
68.94 %
27.13 %
11.75 %
Jan 1, 2019
69.88 %
26.32 %
13.76 %
Jan 1, 2020
69.94 %
24.61 %
23.61 %

GSK plc Stock Revenue, EBIT, Earnings per Share

The GSK plc earnings per share therefore indicates how much revenue GSK plc has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2006
4.07 GBP
1.34 GBP
0.95 GBP
Jan 1, 2007
4.08 GBP
1.32 GBP
0.94 GBP
Jan 1, 2008
4.66 GBP
1.54 GBP
0.88 GBP
Jan 1, 2009
5.55 GBP
1.73 GBP
1.08 GBP
Jan 1, 2010
5.54 GBP
0.97 GBP
0.32 GBP
Jan 1, 2011
5.37 GBP
1.6 GBP
1.03 GBP
Jan 1, 2012
5.3 GBP
1.58 GBP
0.92 GBP
Jan 1, 2013
5.39 GBP
1.46 GBP
1.11 GBP
Jan 1, 2014
4.73 GBP
1.13 GBP
0.57 GBP
Jan 1, 2015
4.89 GBP
1.02 GBP
1.72 GBP
Jan 1, 2016
7.1 GBP
1.79 GBP
0.23 GBP
Jan 1, 2017
7.64 GBP
2.02 GBP
0.39 GBP
Jan 1, 2018
7.75 GBP
2.1 GBP
0.91 GBP
Jan 1, 2019
8.41 GBP
2.21 GBP
1.16 GBP
Jan 1, 2020
6.04 GBP
1.49 GBP
1.43 GBP

GSK plc business model & stock analysis

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. The company is headquartered in Brentford, Middlesex and currently employs 94,066 full-time employees. The firm operates through two segments: Pharmaceuticals and Vaccines. The firm focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The firm makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. The company has a portfolio of medicines in respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.

GSK plc Segments

GSK plc Revenue by Segment (1/4)

  • 3 Years

  • Max

Commercial Operations
Specialty Medicine
Specialty Medicines
General Medicines
HIV, oncology, immuno-inflammation, respiratory and other
Vaccines
Meningitis, influenza, shingles, established vaccines
Sub Total
Vaccines [member]
Respiratory
Respiratory [member]
HIV
HIV [member]
Shingles
Other General Medicines
Established Vaccines
Established Vaccines [member]
Respiratory/Immunology and Other
Shingles [member]
Immuno inflammation respiratory and other
Meningitis
RSV
Meningitis [member]
Pandemic
Oncology
Influenza [member]
Influenza
Pandemic Vaccines
Details
Date
Commercial Operations
Specialty Medicine
Specialty Medicines
General Medicines
HIV, oncology, immuno-inflammation, respiratory and other
Vaccines
Meningitis, influenza, shingles, established vaccines
Sub Total
Vaccines [member]
Respiratory
Respiratory [member]
HIV
HIV [member]
Shingles
Other General Medicines
Established Vaccines
Established Vaccines [member]
Respiratory/Immunology and Other
Shingles [member]
Immuno inflammation respiratory and other
Meningitis
RSV
Meningitis [member]
Pandemic
Oncology
Influenza [member]
Influenza
Pandemic Vaccines
Jan 1, 2021
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
Jan 1, 2022
29.32 B GBP
11.27 B GBP
0 GBP
10.12 B GBP
0 GBP
0 GBP
0 GBP
7.87 B GBP
7.94 B GBP
0 GBP
6.55 B GBP
0 GBP
5.75 B GBP
0 GBP
3.57 B GBP
0 GBP
3.09 B GBP
0 GBP
2.96 B GBP
2.61 B GBP
0 GBP
0 GBP
1.12 B GBP
2.31 B GBP
602 M GBP
714 M GBP
0 GBP
64 M GBP
Jan 1, 2023
0 GBP
0 GBP
10.24 B GBP
10.22 B GBP
10.2 B GBP
9.86 B GBP
9.71 B GBP
0 GBP
0 GBP
6.83 B GBP
0 GBP
6.44 B GBP
0 GBP
3.45 B GBP
3.4 B GBP
3.27 B GBP
0 GBP
3.03 B GBP
0 GBP
0 GBP
1.26 B GBP
1.24 B GBP
0 GBP
44 M GBP
731 M GBP
0 GBP
504 M GBP
150 M GBP

GSK plc Revenue by Segment (2/4)

  • Max

Commercial Operations
Details
Date
Commercial Operations
Jan 1, 2021
0 GBP
Jan 1, 2022
0 GBP
Jan 1, 2023
30.33 B GBP

GSK plc Revenue by Segment (3/4)

  • 3 Years

  • Max

Consumer Healthcare [member]
Details
Date
Consumer Healthcare [member]
Jan 1, 2021
0 GBP
Jan 1, 2022
0 GBP
Jan 1, 2023
0 GBP

GSK plc Revenue by Segment (4/4)

  • 3 Years

  • Max

Pharmaceuticals [member]
New And Speciality
Consumer Healthcare [member]
Sub Total
Vaccines [member]
Established Pharmaceuticals [member]
Respiratory [member]
HIV [member]
Established Vaccines [member]
Shingles [member]
Oral Care [member]
Pain Relief
Digestive Health and Other
Vitamins Minerals and Supplements
Respiratory Health
Meningitis [member]
Pandemic
Immuno inflammation [member]
Oncology
Influenza [member]
Pandemic Vaccines
Brands Divested
Details
Date
Pharmaceuticals [member]
New And Speciality
Consumer Healthcare [member]
Sub Total
Vaccines [member]
Established Pharmaceuticals [member]
Respiratory [member]
HIV [member]
Established Vaccines [member]
Shingles [member]
Oral Care [member]
Pain Relief
Digestive Health and Other
Vitamins Minerals and Supplements
Respiratory Health
Meningitis [member]
Pandemic
Immuno inflammation [member]
Oncology
Influenza [member]
Pandemic Vaccines
Brands Divested
Jan 1, 2021
17.73 B GBP
9.97 B GBP
9.61 B GBP
9.46 B GBP
6.78 B GBP
7.76 B GBP
2.86 B GBP
4.78 B GBP
2.97 B GBP
1.72 B GBP
2.73 B GBP
2.28 B GBP
1.8 B GBP
1.51 B GBP
1.13 B GBP
961 M GBP
958 M GBP
885 M GBP
489 M GBP
679 M GBP
447 M GBP
151 M GBP
Jan 1, 2022
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
Jan 1, 2023
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP
0 GBP

GSK plc Eulerpool Fair Value

GSK plc historical P/E ratio, EBIT multiple, and P/S ratio

GSK plc annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

GSK plc shares outstanding

The number of shares was GSK plc in 2025 — This indicates how many shares 4.117 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2006
5.7 B base_Shares
Jan 1, 2007
5.57 B base_Shares
Jan 1, 2008
5.23 B base_Shares
Jan 1, 2009
5.11 B base_Shares
Jan 1, 2010
5.13 B base_Shares
Jan 1, 2011
5.1 B base_Shares
Jan 1, 2012
4.99 B base_Shares
Jan 1, 2013
4.92 B base_Shares
Jan 1, 2014
4.87 B base_Shares
Jan 1, 2015
4.89 B base_Shares
Jan 1, 2016
3.93 B base_Shares
Jan 1, 2017
3.95 B base_Shares
Jan 1, 2018
3.98 B base_Shares
Jan 1, 2019
4.01 B base_Shares
Jan 1, 2020
4.03 B base_Shares

GSK plc Dividend History

37 years of dividend payments · 2 consecutive increases

YearAnnual DividendYoY ChangePayments
20260.18GBPYTD—1×
Feb 19, 20260.18GBP↑ 12.5%1/1
20250.84GBP↑ 37.7%5×
Feb 20, 20250.16GBP↑ 6.7%1/5
Feb 21, 20250.2GBP↑ 25.0%2/5
May 15, 20250.16GBP↓ 20.0%3/5
Aug 14, 20250.16GBP 0.0%4/5
Nov 13, 20250.16GBP 0.0%5/5
20240.61GBP↑ 9.4%4×
20230.56GBP↓ 16.8%4×
20220.67GBP↓ 16.3%4×
20210.8GBP 0.0%4×
20200.8GBP 0.0%4×
20190.8GBP 0.0%4×
20180.8GBP 0.0%4×
20170.8GBP 0.0%4×

GSK plc dividend history and estimates

In 2025, GSK plc paid a dividend amounting to 0.84 GBP. Dividend means that GSK plc distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2006
0.53 GBP
0 GBP
Jan 1, 2007
0.57 GBP
0 GBP
Jan 1, 2008
0.62 GBP
0 GBP
Jan 1, 2009
0.67 GBP
0 GBP
Jan 1, 2010
0.71 GBP
0 GBP
Jan 1, 2011
0.76 GBP
0 GBP
Jan 1, 2012
0.81 GBP
0 GBP
Jan 1, 2013
0.86 GBP
0 GBP
Jan 1, 2014
0.89 GBP
0 GBP
Jan 1, 2015
0.89 GBP
0 GBP
Invalid Date
0.8 GBP
0.15 GBP
Jan 1, 2017
0.8 GBP
0 GBP
Jan 1, 2018
0.8 GBP
0 GBP
Invalid Date
0 GBP
0.8 GBP
Jan 1, 2020
0.8 GBP
0 GBP

GSK plc dividend payout ratio

In 2025, GSK plc had a payout ratio of 46.78%. The payout ratio indicates the percentage of the company's profits that GSK plc distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2006
70.18 %
Jan 1, 2007
75.36 %
Jan 1, 2008
88.39 %
Jan 1, 2009
77.15 %
Jan 1, 2010
277.75 %
Jan 1, 2011
91.69 %
Jan 1, 2012
110.21 %
Jan 1, 2013
96.35 %
Jan 1, 2014
194.93 %
Jan 1, 2015
64.49 %
Jan 1, 2016
430.11 %
Jan 1, 2017
263.16 %
Jan 1, 2018
109.89 %
Jan 1, 2019
86.39 %
Jan 1, 2020
70.42 %
Price targets and forecasts for GSK plc are not yet available.

GSK plc Earnings Estimates

GSK plc Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
4/24/20240.36GBP7.29 BGBP2024 Q1
1/31/20240.32GBP7.75 BGBP2023 Q4
2/1/20230.26GBP7.48 BGBP2022 Q4
11/2/20220.41GBP7.44 BGBP2022 Q3
7/27/20220.3GBP6.6 BGBP2022 Q2
4/27/20220.39GBP9.13 BGBP2022 Q1
2/9/20220.32GBP9.64 BGBP2021 Q4
10/27/20210.37GBP8.86 BGBP2021 Q3
7/28/20210.26GBP7.67 BGBP2021 Q2
4/28/20210.28GBP8 BGBP2021 Q1
...

EESG©

Eulerpool ESG Scorecard© for the GSK plc stock

88/100
83
Environment
96
Social
85
Governance
E

Environment

20
Scope 1 - Direct Emissions521,000
Scope 2 - Indirect emissions from purchased energy234,000
Scope 3 - Indirect emissions within the value chain4,640,000
Total CO₂ emissions755,000
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides—
Palm Oil
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees48
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

GSK plc shareholder structure

% Name
3.05956%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
3.02486%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
2.41384%
Dodge & Cox
Dodge & Cox
1.70719%
Norges Bank Investment Management (NBIM)
Norges Bank Investment Management (NBIM)
1.56216%
GlaxoSmithKline Plc ESOP
GlaxoSmithKline Plc ESOP
1.46997%
BlackRock Advisors (UK) Limited
BlackRock Advisors (UK) Limited
1.37731%
BlackRock Investment Management (UK) Ltd.
BlackRock Investment Management (UK) Ltd.
1.33483%
Wellington Management Company, LLP
Wellington Management Company, LLP
1.30546%
Silchester International Investors, L.L.P.
Silchester International Investors, L.L.P.
0.98003%
Independent Franchise Partners LLP
Independent Franchise Partners LLP
...

GSK plc Executives and Management Board

DW

Dame Emma Walmsley

(55)

Chief Executive Officer, Executive Director · since 2011

Compensation10.56 M GBP
JB

Ms. Julie Brown

(62)

Chief Financial Officer, Executive Director · since 2023

Compensation4.17 M GBP
SS

Sir Jonathan Symonds

(65)

Independent Non-Executive Chairman of the Board

Compensation781,000 GBP
HB

Dr. Hal Barron

(62)

Non-Executive Director · since 2018

Compensation462,000 GBP
CB

Mr. Charles Bancroft

(65)

Senior Independent Non-Executive Director

Compensation333,000 GBP

GSK plc Supply Chain

Frequently asked questions about GSK plc

All fundamentals and in-depth analysis of GSK plc

Our stock analysis for GSK plc Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of GSK plc Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

GSK plc Stock
GSK plc Revenue→
GSK plc Stock
GSK plc Net Income→
GSK plc Stock
GSK plc P/E→
GSK plc Stock
GSK plc P/S→
GSK plc Stock
GSK plc EBIT→
GSK plc Stock
GSK plc Dividend→
GSK plc Stock
GSK plc Directors Dealings→
GSK plc Stock
GSK plc Stocks→
GSK plc Stock
GSK plc Market capitalization→
GSK plc Stock
GSK plc Debt→
GSK plc Stock
GSK plc Liabilities→
GSK plc Stock
GSK plc Equity→
GSK plc Stock
GSK plc AAQS→
GSK plc Stock
GSK plc Employees→
GSK plc Stock
GSK plc ROE→
GSK plc Stock
GSK plc ROA→
GSK plc Stock
GSK plc ROCE→